Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Bill J. Smith, George Stepan et al.|Molecular Pharmaceutics|2023Cited by 52
539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in HumansJim Zheng, Winston C. Tse, Stephen R. Yant et al.|Open Forum Infectious Diseases|2018Cited by 15
Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Raju Subramanian, Bing Lu et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13